Literature DB >> 11136389

What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

P Petrini1.   

Abstract

In order to prevent arthropathy, prophylaxis has to start at a young age before recurrent joint bleedings have taken place. The use of central venous lines has facilitated an early beginning to treatment, but due to side-effects, most European paediatricians prefer peripheral injections whenever possible. By starting primary prophylaxis at the age of 1--2 years with one injection weekly, the need for surgical implants may be reduced. In this study, only four of 34 boys born 1988--98 with severe haemophilia A or B needed a Port-a-Cath for primary prophylaxis. Trough levels were measured in these patients and 79% showed a trough level < 1%, while 21% reached a level > 1%. Despite this, joint bleedings during 1998 were rare in both groups [0--4] and 59% of the boys with trough levels < 1% did not report any haemartroses during that year. Mean annual joint bleedings were the same in both groups [0.70, 0.71]. The lowest effective level of factors VIII and IX must be determined individually for each patient on primary or secondary prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136389     DOI: 10.1046/j.1365-2516.2001.00471.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  12 in total

1.  Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades.

Authors:  Annelies Nijdam; Carmen Altisent; Manuel D Carcao; Ana R Cid; Ségolène Claeyssens-Donadel; Karin Kurnik; Rolf Ljung; Beatrice Nolan; Pia Petrini; Helen Platokouki; Anne Rafowicz; Angela E Thomas; Kathelijn Fischer
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

2.  The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia.

Authors:  Sweta Gupta; Azfar-E-Alam Siddiqi; J Michael Soucie; Marilyn Manco-Johnson; Roshni Kulkarni; Heidi Lane; Robina Ingram-Rich; Joan C Gill
Journal:  Br J Haematol       Date:  2013-02-22       Impact factor: 6.998

Review 3.  Low Dose Prophylaxis in Hemophilia Care.

Authors:  Neeraj Sidharthan; Remya Sudevan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-15       Impact factor: 0.900

4.  Systemic delivery of factor IX messenger RNA for protein replacement therapy.

Authors:  Suvasini Ramaswamy; Nina Tonnu; Kiyoshi Tachikawa; Pattraranee Limphong; Jerel B Vega; Priya P Karmali; Pad Chivukula; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-15       Impact factor: 11.205

Review 5.  Primary prophylaxis in children with haemophilia.

Authors:  Antonio Coppola; Mirko Di Capua; Ciro De Simone
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

Review 6.  Treatment strategies in children with hemophilia.

Authors:  Pia Petrini
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

7.  Treatment of hemophilia: a review of current advances and ongoing issues.

Authors:  Antonio Coppola; Mirko Di Capua; Matteo Nicola Dario Di Minno; Mariagiovanna Di Palo; Emiliana Marrone; Paola Ieranò; Claudia Arturo; Antonella Tufano; Anna Maria Cerbone
Journal:  J Blood Med       Date:  2010-08-30

8.  Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.

Authors:  Byung Suk Moon; Jun Seok Choi; Chur Woo You
Journal:  Korean J Pediatr       Date:  2013-07-19

Review 9.  Haemophilia and joint disease: pathophysiology, evaluation, and management.

Authors:  Karin Knobe; Erik Berntorp
Journal:  J Comorb       Date:  2011-12-27

10.  Impact of prophylaxis on health-related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries.

Authors:  Koyo Usuba; Victoria E Price; Victor Blanchette; Audrey Abad; Carmen Altisent; Loretta Buchner-Daley; Jorge D A Carneiro; Brian M Feldman; Kathelijn Fischer; John Grainger; Susanne Holzhauer; Koon-Hung Luke; Sandrine Meunier; Margareth Ozelo; Ling Tang; Sandra V Antunes; Paula Villaça; Cindy Wakefield; Gilian Wharfe; Runhui Wu; Nancy L Young
Journal:  Res Pract Thromb Haemost       Date:  2019-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.